Study summary

CAR T cells aimed at mutant calreticulin wiped out the disease-starting stem cells in mice

Mutant-CALR CAR T-cell study (laboratory) · Laboratory (preclinical) study · Published November 2026, Blood

What was tested

CAR T cells built with a high-affinity antibody against mutant calreticulin (CALR), the driver in about a quarter of ET cases, tested in mice carrying patient cells.

What they found

• The CAR T cells eliminated all detectable disease-sustaining stem cells in mice.
• Normal blood production was preserved.

What it means

Supports the idea of a transplant-free cure for CALR-mutant disease; antibodies against the same target are already in phase 3.